Sarepta Wins First Phase of Nippon Shinyaku Gene-Therapy Trial

Sarepta Therapeutics Inc. convinced a federal jury to uphold a patent Nippon Shinyaku Co. admitted its Viltepso drug infringes, and to void a patent it conceded infringing with its competing genetic therapy for Duchenne muscular dystrophy.

Sarepta claimed a near-total win in the first of a two-phase trial, convincing jurors that Nippon Shinyaku’s US Patent No. 10,385,092 is invalid for covering an obvious invention, mooting Sarepta’s concession that its Vyondys 53 drug infringes, according to a verdict issued Thursday in the US District Court for the District of Delaware. Both parties conceded infringement ahead of the trial, according to pretrial ...